News
The FDA is shutting the door to imports of certain endoscope hardware manufactured by Olympus, saying that a production site in Japan has failed to meet quality requirements. | The FDA is shutting the ...
While the IPO landscape remains icy, Minovia Therapeutics is skating into the market using a special purpose acquisition ...
The company’s medtech wing has launched the Polyphonic AI Fund for Surgery, and will be taking proposals from academic and ...
Kymera Therapeutics sweetened news of a setback Wednesday, revealing that Sanofi is pulling back from its lead IRAK4 degrader ...
Arbutus Biopharma had made no secret of its plans to step up its work on imdusiran. | Arbutus had made no secret of its desire to step up its plans for imdusiran. Now, the company has regained the ...
Biogen has pointed to an early readout from a small phase 1 trial as evidence that its antisense oligonucleotide salanersen ...
Bayer-owned BlueRock Therapeutics is laying off 50 employees and shuttering its research labs in Cambridge, Mass., in order ...
Sangamo Therapeutics’ investigational gene therapy appears to improve kidney function at 52 weeks for patients with a rare genetic disorder. | Sangamo Therapeutics’ investigational gene therapy ...
The surgical sealant developer Tissium obtained a groundbreaking FDA clearance for its method of reconnecting severed nerves, ...
ForSight Robotics may be seeing stars after raising $125 million in venture capital funding to power the first human clinical ...
Rivus Pharmaceuticals’ fat-busting, muscle-sparing drug candidate reduced liver fat in a phase 2 trial while showcasing the ...
Mean body weight reductions after 24 weeks ranged from 8.2% to 10.3% in the MDR-001 cohorts, versus 2.5% in the placebo arm.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results